Quick Summary IPO Details: Ceribell launched its IPO at $17 per share, closing above $25. Technology Focus: Portable EEG system for emergency and ICU use.
Quick Summary Focus: Onward Medical licenses a brain-computer interface (BCI) chip from CEA-Clinatec. Goal: Enable spinal cord injury patients to regain communication between brain and
Quick Summary Therapy: Apitegromab, a muscle-targeted monoclonal antibody Trial Outcome: Significant improvements in motor function for non-ambulatory SMA patients Regulatory Plans: Scholar Rock intends to
Quick Summary Device: Embecta’s new disposable insulin patch pump with a 300-unit reservoir. FDA Clearance: Approved as a tubeless insulin delivery system for both Type
Quick Summary Acquisition Value: Veracyte acquired C2i Genomics for $70 million, with an additional $25 million contingent on performance milestones. Strategic Goal: To expand Veracyte’s
Quick Summary Partnership Focus: Nvidia, Amgen’s deCode Genetics, and Recursion Pharmaceuticals collaborate to harness AI in drug discovery. Platform: Nvidia’s BioNeMo platform will be used
Quick Summary Device: Butterfly Network’s iQ3 handheld ultrasound FDA Clearance: Cleared as a point-of-care ultrasound device, featuring advanced 3D capabilities and AI-powered imaging modes. Technological
Quick Summary Trial Result: Eli Lilly’s Taltz (ixekizumab) outperformed Janssen’s Tremfya (guselkumab) in a head-to-head Phase IV study. Primary Outcome: 41% of patients treated with
Quick Summary Partnership: BD (Becton, Dickinson and Company) teams up with Ypsomed to develop advanced self-injection systems. Focus: Enhancing patient experience for high-viscosity biologics often
Quick Summary Key Result: Intellia Therapeutics reports up to an 81% reduction in angioedema attacks for high-dose recipients in its Phase 2 trial. Therapeutic Potential:
